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ABSTRACT
Sphingosine kinases (two isoforms termed SK1 and SK2) catalyse the formation 
of the bioactive lipid sphingosine 1-phosphate. We demonstrate here that the SK2 
inhibitor, ABC294640 (3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-
4-ylmethyl)amide) or the SK1/SK2 inhibitor, SKi (2-(p-hydroxyanilino)-4-(p-
chlorophenyl)thiazole)) induce the proteasomal degradation of SK1a (Mr = 42 kDa) 
and inhibit DNA synthesis in androgen-independent LNCaP-AI prostate cancer cells. 
These effects are recapitulated by the dihydroceramide desaturase (Des1) inhibitor, 
fenretinide. Moreover, SKi or ABC294640 reduce Des1 activity in Jurkat cells and 
ABC294640 induces the proteasomal degradation of Des1 (Mr = 38 kDa) in LNCaP-
AI prostate cancer cells. Furthermore, SKi or ABC294640 or fenretinide increase the 
expression of the senescence markers, p53 and p21 in LNCaP-AI prostate cancer cells. 
The siRNA knockdown of SK1 or SK2 failed to increase p53 and p21 expression, but 
the former did reduce DNA synthesis in LNCaP-AI prostate cancer cells. Moreover, 
N-acetylcysteine (reactive oxygen species scavenger) blocked the SK inhibitor-
induced increase in p21 and p53 expression but had no effect on the proteasomal 
degradation of SK1a. In addition, siRNA knockdown of Des1 increased p53 expression 
while a combination of Des1/SK1 siRNA increased the expression of p21. Therefore, 
Des1 and SK1 participate in regulating LNCaP-AI prostate cancer cell growth and this 
involves p53/p21-dependent and -independent pathways. Therefore, we propose 
targeting androgen-independent prostate cancer cells with compounds that affect 
Des1/SK1 to modulate both de novo and sphingolipid rheostat pathways in order to 
induce growth arrest.
INTRODUCTION
The bioactive lipid, sphingosine 1-phosphate (S1P) 
is formed by the phosphorylation of sphingosine and 
this reaction is catalysed by two isoforms of sphingosine 
kinase (SK1 and SK2), which are encoded by different 
genes and exhibit distinct subcellular localisations, 
biochemical properties and functions (see [1] for review). 
Once produced, S1P can either be exported from cells 
(through transporter proteins e.g. Spns2 and certain 
$%&WUDQVSRUWHUVDQGDFWDVDOLJDQGRQDIDPLO\RI¿YH
63VSHFL¿F*SURWHLQFRXSOHGUHFHSWRUV63
1-5
) [2] or, 
LIUHWDLQHGZLWKLQWKHFHOOELQGWRDQGUHJXODWHVSHFL¿F
intracellular target proteins. For instance, SK2 catalyses 
the formation of S1P in the nucleus and the subsequently 
formed S1P inhibits HDAC1/2 activity to induce c-fos 
and p21 expression [3]. Dephosphorylation of S1P is 
catalysed by S1P phosphatases that recycle sphingosine, 
which is then acylated to ceramide. Alternatively, S1P 
can be irreversibly cleaved by S1P lyase to produce (E)-2 
hexedecenal and phosphoethanolamine [1].
A feature of SK1 inhibitors is that they induce the 
ubiquitin-proteasomal degradation of SK1 in solid cancer 
cell lines [46] and proliferating vascular smooth muscle 
cells [4, 7, 8]. The ubiquitin-proteasomal degradation 
of SK1 is correlated with binding and/or inhibition 
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of SK1 catalytic activity. However, other inhibitors 
of SK1 and SK2 such as SKi (2-(p-hydroxyanilino)-
4-(p-chlorophenyl) thiazole) induce the proteasomal 
degradation of SK1 via a mechanism that is only 
partially dependent on direct binding to SK1 [4]. Recent 
studies have demonstrated that SK2 might also have an 
important role in cancer, For instance, the aryladamantane 
compound, ABC294640 (3-(4-chlorophenyl)-adamantane-
1-carboxylic acid (pyridin-4-ylmethyl)amide), which 
is reported to be a selective inhibitor of SK2 activity, is 
in phase 2 clinical trials for diffuse B-cell lymphoma. 
ABC294640 is a competitive (with sphingosine) inhibitor 
of SK2 activity with a K
i
 of 9.8 PM, and reduces S1P 
formation in cancer cells [9]. Oral administration of 
ABC294640 to mice with mammary adenocarcinoma 
xenografts results in dose-dependent anti-tumor activity 
associated with reduced tumor S1P levels and apoptosis 
[9]. Indeed, ABC294640 also reduces clonogenic survival 
and viability of ovarian cancer lines and increases 
caspase cleavage and apoptosis of Kaposi's sarcoma-
associated herpes virus positive patient-derived primary 
effusion lymphoma cells [10]. ABC294640 also promotes 
autophagic death of A-498 kidney carcinoma cells, PC-3 
prostate and MDA-MB-231 breast adenocarcinoma cells 
[11]. Indeed, ABC294640 delays tumor growth in severe 
FRPELQHGLPPXQRGH¿FLHQWPLFHZLWK$[HQRJUDIWV
via an autophagic mechanism. ABC294640 also reduces 
colorectal cancer growth in vitro and in vivo [12] and 
decreases tumor incidence in an azoxymethane (AOM)/
dextran sulfate sodium (DSS) mouse model, suggesting 
WKDW 6. KDV D UROH LQ LQÀDPPDWLRQLQGXFHG FDQFHU
progression [13].
We have previously demonstrated that SKi induces 
the proteasomal degradation of SK1a and SK1b (which 
has an 86 amino-acid N-terminal extension compared 
with SK1a) in androgen-sensitive LNCaP prostate cancer 
cells and this results in a reduction in S1P levels and an 
increase in sphingosine and C22:0 and C24:0 ceramide 
levels. This is associated with the induction of apoptosis 
[4]. SKi also induces proteasomal degradation of SK1a 
in androgen-independent LNCaP-AI cells, but fails to 
reduce SK1b levels [4] and does not increase C22:0 and 
C24:0 ceramide levels. In this case, androgen-independent 
LNCaP-AI cells are resistant to apoptosis induced by SKi. 
Nevertheless, SKi is still able to inhibit DNA synthesis 
indicative of promoting growth arrest of these cells. 
The inability of SKi to reduce SK1b expression levels 
appears due to a compensatory increase in SK1b mRNA 
expression in these cells. Thus, combined treatment 
with SK1 siRNA (to prevent mRNA translation of SK1a 
DQGVLJQL¿FDQWO\6.EDQG6.LUHVXOWVLQDSRSWRVLVRI
androgen-independent LNCaP-AI cells [4]. 
We have therefore investigated the role of SK1 and 
SK2 in androgen-independent LNCaP-AI cell growth 
using the SK1/2 inhibitor, SKi and the SK2 selective 
LQKLELWRU$%& 2XU ¿QGLQJV LQGLFDWH WKDW WKHVH
compounds induce growth arrest predominantly by 
inducing the proteasomal degradation of SK1 and by 
inhibiting dihydroceramide desaturase (Des1), which 
catalyses the conversion of dihydroceramide to ceramide. 
Thus, growth arrest appears to involve modulation of both 
the de novo ceramide pathway and sphingolipid rheostat 
(relative effects of ceramide/S1P) pathways.
RESULTS
ABC294640 induces the proteasomal 
degradation of SK1: Reversal by MG132
Recently, the SK2 selective inhibitor, ABC294640 
was demonstrated to induce proteasomal degradation of 
c-Myc and myeloid cell leukemia 1 (Mcl-1) in multiple 
myeloma cells [14]. We had previously demonstrated that 
the SK1/2 inhibitor, SKi also induced the proteasomal 
degradation of c-Myc in LNCaP prostate cancer cells 
[15]. In contrast, the SK2 selective inhibitor ((R)-FTY720 
methylether (ROMe [16]) failed to modulate c-Myc 
expression in these cells [15]. Therefore, we considered 
that the ability of ABC294640 to induce proteasomal 
degradation of c-Myc is not a typical property of SK2 
inhibitors but which might be mediated through an indirect 
effect on the ubiquitin-proteasomal degradation of SK1a in 
androgen-independent LNCaP-AI cells. Indeed, we show 
here that ABC294640 (525 PM) reduced the expression 
of SK1a (Mr = 42 kDa) in androgen-independent 
LNCaP-AI cells and this was prevented by pre-treating 
WKHVH FHOOV ZLWK WKH SURWHDVRPDO LQKLELWRU 0*
(Figure 1A). Therefore, although ABC294640 is an SK2 
selective inhibitor with no direct inhibitor effect against 
recombinant SK1 at concentrations as high as 100 PM [9], 
it is able to remove SK1a from prostate cancer cells via an 
LQGLUHFWPHFKDQLVP7KHVH¿QGLQJVZHUHVLPLODUWRWKRVH
obtained with the dual SK1/SK2 inhibitor, SKi, which 
can activate the proteasome and promote accelerated 
ubiquitin-proteasomal degradation of SK1a in androgen-
sensitive and androgen independent LNCaP prostate 
cancer cells [4]. We therefore, tested the effect of various 
SK1- and SK2-selective inhibitors on the proteasomal 
degradation of SK1a in order to establish whether the 
inhibition of SK2 activity by ABC294640 is required 
to induce the proteasomal degradation of SK1a. In this 
regard, the SK1 selective inhibitors PF-543 [17], (which 
we have shown inhibits SK1 activity with a K
i 
= 14 nM 
[8] and inhibits SK2 activity by 33% at 5 PM PF-543) and 
RB-005 (which inhibits SK1 with a K
i
 = 3 PM and inhibits 
SK2 activity by < 10% at 50 PM RB-005 [7]) induced 
the proteasomal degradation of SK1a in LNCaP-AI cells 
(Figure 1B). However, treatment of LNCaP-AI cells with 
the SK2 selective inhibitors (R)-FTY720 methylether 
(ROMe) (which has a K
i 
= 14 PM, and does not inhibit 
SK1 activity at 100 PM ROMe [16]) or F-02 [8] failed 
to reduce SK1a expression in these cells (Figure 1B). We 
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have previously shown that ROMe affects the metabolome 
of LNCaP cells at this concentration and is therefore active 
LQWKHVHFHOOV>@:HFRQ¿UPKHUHWKDWWKHWUHDWPHQWRI
LNCaP-AI cells with SKi (10 PM) induced a decrease 
in the expression of SK1a and this could be reversed by 
SUHWUHDWPHQWRIWKHFHOOVZLWK0*)LJXUH%
Previous reports have demonstrated that SKi 
can also induce the lysosomal degradation of SK1 by 
cathepsin B1 [18]. However, pre-treatment of LNCaP-AI 
cells with the cathepsin B1 inhibitor, CA074Me had no 
effect on the ability of ABC294640 or SKi to induce the 
decrease in expression of SK1a (Figure 1C). The effects 
of SKi or ABC294640 on the proteasomal degradation of 
SK1a were time-dependent (Figure 1D) and associated 
ZLWKDVLJQL¿FDQWFRQFHQWUDWLRQGHSHQGHQWLQKLELWLRQRI
DNA synthesis, and which was recapitulated by siRNA 
knockdown of SK1 but not SK2 (Figure 2A, 2B).
Effect on p53 and p21 expression
Treatment of LNCaP-AI cells with ABC294640 or 
SKi induced a concentration- and time-dependent increase 
in p53 and p21 expression (Figure 1D, 1E), which are 
markers of growth arrest and senescence, in androgen-
independent LNCaP-AI cells. This was fully recapitulated 
with nutlin (Figure 1E), an inhibitor of the E3 ligase, mdm2 
which catalyses ubquitination of p53 and regulates its 
stability in cells. In common with SKi and ABC294640, 
nutlin induced a concentration-dependent inhibition of DNA 
synthesis (Figure 2C) consistent with a p53/p21-dependent 
growth arrest. In contrast, the SK1 selective inhibitor, 
PF- 543 and the SK2 selective inhibitor, ROMe failed to 
induce an increase in p53 expression (Supplementary 
Figure 1). An individual role for SK1 and SK2 in regulating 
SSH[SUHVVLRQZDVH[FOXGHGEDVHGRQWKH¿QGLQJWKDW
siRNA knockdown of either kinase or both together had no 
effect on p53 or p21 expression (Figure 2B). 
The role of dihydroceramide desaturase
We have previously reported that the treatment of 
prostate cancer cells with SKi reduces S1P levels and 
markedly increases sphingosine and dihydroceramide 
levels in these cells; the latter is consistent with inhibition 
of dihydroceramide desaturase, Des1 [4]. Indeed, we show 
here that ABC294640 or SKi inhibit Des1 activity in intact 
Jurkat cells (Figure 3). ABC294640 exhibits an IC
50
 = 
íPM (n = 3) and SKi exhibited an IC
50 
= 0.63
0.69 PM (n = 2). These were very similar with the IC
50
 
values for inhibition of DNA synthesis of 19.3 PM and 
1.29 PM for ABC294640 and SKi respectively in LNCaP-
AI cells (Figure 2A). In addition, Cingolani et al. [19] 
have reported a K
i
 (0.3 PM) for inhibiton of Des1 by SKi. 
In addition, we show here that treatment of LNCaP-AI 
cells with ABC294640 induced a decrease in Des1 (Mr = 
38 kDa) expression that was reversed by the proteasomal 
LQKLELWRU 0* )LJXUH  LQGLFDWLQJ DQ DGGLWLRQDO
level of regulation of Des1 by ABC294640. We therefore 
investigated whether the effects of ABC294640 and SKi 
on SK1a, p53 and p21 expression are mediated through 
inhibition of Des1 activity. We used the Des1 inhibitor, 
fenretinide [20] which induced a reduction in SK1a 
expression and an increase in p53 and p21 expression 
(Figure 4A). Fenretinide also induced a concentration-
dependent inhibition of DNA synthesis in androgen-
independent LNCaP-AI cells (Figure 4B). 
p53 and p21 expression but not proteasomal 
degradation of SK1 is regulated by an oxidative 
stress-dependent mechanism
2XU ¿QGLQJV VXJJHVW WKDW 'HV DFWLYLW\ QRUPDOO\
functions to restrain proteasomal activity and that 
inhibition of the enzyme with SKi or ABC294640 results 
in the ubiquitin-proteasomal degradation of SK1a and 
Des1. In addition, Des1 appears to exert a regulatory 
LQÀXHQFHRQSDQGSH[SUHVVLRQ7KHUHIRUHZHQH[W
investigated whether SK1a, p53 and p21 are linked in 
a sequential linear or convergent parallel pathway to 
regulate growth of androgen-independent LNCaP-AI cells.
We have previously shown that SKi induces an 
oxidative stress response in androgen-independent 
LNCaP-AI cells as evidenced by the accumulation 
of oxidised glutathione and switching from aerobic 
glycolysis to the pentose phosphate pathway, which 
attempts to counteract oxidative stress by production of 
NADPH [15]. Moreover, Mercado et al. [21] demonstrated 
that SKi regulates Nrf2, a redox-sensitive transcription 
factor. Indeed, the effect of ABC294640 or SKi observed 
here on p53 and p21 expression was reversed by the 
reactive oxygen species scavenger, N-acetyl cysteine 
(Figure 5A). However, the effect of ABC294640 or SKi on 
the proteasomal degradation of SK1a was not modulated 
by N-acetyl cysteine (Figure 5B). In addition, N-acetyl 
cysteine had no effect on the ABC294640-induced 
proteasomal degradation of Des1 (Figure 5C), suggesting 
that the oxidative stress response is down stream of Des1.
7KHVH¿QGLQJVSODFH6.DDQGSSRQVHSDUDWH
pathways. However, siRNA knockdown of Des1 increased 
p53 expression while a combination of Des1/SK1 siRNA 
increased expression of p21 (Figure 6). Therefore, p53 
expression is regulated by Des1, while p21 is regulated 
by a combination of Des1 and SK1a. The Des1-dependent 
regulation of p21 and p53 appears to involve an oxidative 
stress response. Des1 activity has also been reported to be 
inhibited by oxidative stress [22].
DISCUSSION
We have demonstrated that SK1 and Des1 
participate in regulating growth of androgen-independent 
prostate cancer cells and this involves p53/p21-dependent 
and -independent pathways (Figure 7). This is supported 
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Figure 1: Effect of various SK inhibitors on the proteasomal degradation of SK1a in androgen-independent LNCaP-
AI cells. /1&D3$,FHOOVZHUHSUHWUHDWHGZLWKRUZLWKRXW0*0RU&$0H0IRUPLQSULRUWRWUHDWPHQWZLWK6.
inhibitors for 24 h. (A:HVWHUQEORWVKRZLQJWKHHIIHFWRI$%&±0RQWKHH[SUHVVLRQRI6.DLQWKHSUHVHQFHDQGDEVHQFH
RI0*$OVRVKRZQLVDEDUJUDSKRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI$%&±0RQWKHSURWHDVRPDOGHJUDGDWLRQRI6.D
5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. *p < 0.05, ***p < 0.001 versus control; (B) Western blot showing the effect 
RI$%&0RU6.L0RU3)Q0RU5%0RU)0RU520H0LQWKHSUHVHQFH
RUDEVHQFHRI0*RQWKHH[SUHVVLRQRI6.D$OVRVKRZQLVDEDUJUDSKRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI6.DQG6.VHOHFWLYH
LQKLELWRUVRQ WKHSURWHDVRPDOGHJUDGDWLRQRI6.D5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. **p < 0.01 versus 
control; (C:HVWHUQEORWVKRZLQJWKHODFNRIHIIHFWRI&$0HRQWKH$%&0RU6.L0LQGXFHGUHGXFWLRQLQ6.D
H[SUHVVLRQ$OVRVKRZQLVDEDUJUDSKRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI&$0H0RQWKH6.L0RU$%&
0LQGXFHGGHJUDGDWLRQRI6.D5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. **p < 0.01 versus control; (D) Western 
EORWVKRZLQJWKHWLPHFRXUVHRI$%&0RU6.L0LQGXFHGFKDQJHVLQ6.DSDQGSH[SUHVVLRQE) Western 
blot showing the concentration-dependence of ABC294640- or SKi- or nutlin on p53 and p21 expression. Also shown in (D) and (E) are 
EDUJUDSKVRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRIQXWOLQRU$%&RU6.LRQWKHLQFUHDVHLQSSDQGGHFUHDVHLQ6.DH[SUHVVLRQ
5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. *p < 0.05, **p < 0.01 versus control. Actin was used a protein loading control 
in western blots. Western blot results are representative of at least three independent experiments.
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Figure 2: Effect of ABC294640, SKi, nutlin or siRNA knock down of SK isoforms on [3H]thymidine incorporation in 
androgen-independent LNCaP-AI cells. Androgen-independent LNCaP-AI cells were treated with ABC294640 or SKi or nutlin for 
24 h or scrambled siRNA or SK1 siRNA or SK2 siRNA for 48 h. (A) Concentration-dependent inhibition of DNA synthesis is induced by 
$%&RU6.L5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments; (B) Western blot showing the effect of SK1 siRNA or 
6.VL51$RQ6.DSDQGSH[SUHVVLRQ6.L0ZDVXVHGDSRVLWLYHFRQWURO$FWLQZDVXVHGDSURWHLQORDGLQJFRQWURO%ORWV
DUHUHSUHVHQWDWLYHRIWKUHHLQGHSHQGHQWH[SHULPHQWV$OVRVKRZQDUHEDUJUDSKVRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI6.VL51$RU6.
VL51$RQ6.DSDQGSH[SUHVVLRQ5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. ***p < 0.001 versus scrambled 
siRNA. The effect of SK1 siRNA or SK2 siRNA on DNA synthesis is also shown. **p < 0.01 versus scrambled siRNA; (C) Concentration-
GHSHQGHQWLQKLELWLRQRI'1$V\QWKHVLVLVLQGXFHGE\QXWOLQ5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments.
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by studies demonstrating that ABC294640 induces 
VLJQL¿FDQW LQKLELWLRQRIJURZWKSUROLIHUDWLRQDQGFHOO
cycle progression in prostate cancer cells [23]. In addition 
SKi induces growth arrest at S phase with a decrease in the 
SURSRUWLRQRI$NLGQH\DGHQRFDUFLQRPDFHOOVLQ*0
SKDVH>@$%& LQGXFHGDQDUUHVW LQ*SKDVH
ZLWKDGHFUHDVHLQWKHSURSRUWLRQRI$FHOOVLQ*0
and S phase [24]. These effects of SKi and ABC294640 
PLJKWUHÀHFWGLIIHUHQWHI¿FDFLHVLQWHUPVRIPRGXODWLQJ
SK1, SK2 and Des1 activities in A498 cells.
We have previously show that the treatment 
of LNCaP prostate cancer cells with SKi results in a 
substantial increase in the levels of several different 
molecular species of dihydroceramide [4] suggesting, in 
agreement with Cingolani et al. [19], that SKi inhibits 
'HV DFWLYLW\ ,QGHHG ZH KDYH FRQ¿UPHG KHUH WKDW
both SKi and ABC294640 inhibit Des1 activity. Here, 
we establish that ABC294640 induces proteasomal 
degradation of Des1. Moreover, Venant et al., [25] have 
also demonstrated that ABC294640 reduces the growth of 
prostate cancer cells and inhibits Des1 activity and this 
is associated with an increase in dihydroceramide levels. 
Others have demonstrated that Des1 activity is inhibited 
by SKi in a non-competitive manner and that inhibition 
was indirect [19]. We propose here that Des1 functions 
to restrain proteasomal activity and that its inhibition by 
SKi or ABC294640, therefore, increases the proteasomal 
degradation of SK1a and Des1. Consistent with this, 
the dihydroceramide desaturase inhibitor, fenretinide 
fully recapitulated the effects of SKi and ABC294640 
in promoting the proteasomal degradation of SK1a in 
androgen-independent LNCaP-AI prostate cancer cells.
The treatment of androgen-independent LNCaP-
AI prostate cancer cells with SKi or ABC294640 or 
fenretinide also induced an increase in the expression 
of p53 and p21. In contrast, treatment of these prostate 
cancer cells with SK1 selective (PF-543) or SK2 selective 
(ROMe) inhibitors alone or siRNA knockdown of SK1 or 
Figure 3: Effect of ABC294640 or SKi on Des1 activity. Des1 activity was measured using Jurkat cells labeled with DhCer-C6-
1%'DQG+3/&DQDO\VLV7KHZHVWHUQEORWGHPRQVWUDWHVWKHHIIHFWRI$%&0IRUKLQWKHSUHVHQFHDQGDEVHQFHRI0*
0RQ'HVH[SUHVVLRQ$FWLQZDVXVHGDSURWHLQORDGLQJFRQWURO5HVXOWVDUHUHSUHVHQWDWLYHRIDWOHDVWWKUHHLQGHSHQGHQWH[SHULPHQWV
$OVRVKRZQLVDEDUJUDSKRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI$%&RQ'HVH[SUHVVLRQ5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRU
n = 3 experiments. **p < 0.01 versus control; ***p < 0.001 versus control.
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SK2 or their combination failed to induce an increase in 
the expression of p53 and p21. Therefore, inhibition or 
NQRFNGRZQRI6.RU6.DORQHLVLQVXI¿FLHQWWRDIIHFW
p53/p21 expression. However, siRNA knockdown of Des1 
increased p53 expression and a combination of Des1/
SK1 siRNA-mediated knockdown induced an increased 
H[SUHVVLRQRIS7KHVH¿QGLQJVVXJJHVWWKDWWKHHIIHFWV
of SKi and ABC294640 on p53 expression are likely 
mediated by Des1 inhibition and this is supported by our 
¿QGLQJWKDWIHQUHWLQLGHLQFUHDVHVSDQGSDQGUHGXFHV
SK1 expression. In contrast, the increase in p21 expression 
by SKi or ABC294640 might involve regulation by both 
Des1 and SK1 (Figure 7). The SKi- and ABC294640-
induced increase in p53 and p21 expression is also blocked 
by scavenging ROS with the anti-oxidant, N-acetyl 
cysteine, suggesting that the regulation of p53 and p21 by 
Des1 involves an oxidative stress response. In addition, 
siRNA knockdown of SK1 inhibited DNA synthesis, which 
was independent of p53 and p21 as these were not affected 
by SK1 siRNA alone. Therefore, growth arrest induced 
by SKi or ABC294640 appears to involve convergence of 
pathways regulated by SK1a and Des1. This is likely by 
modulation of the de novo ceramide pathway at Des1 (with 
regulation of p53 and p21) and proteasomal degradation 
Figure 4: Effect of fenretinide on SK1a, p21 and p53 expression. LNCaP-AI cells were treated with fenretinide for 24 h. (A) 
:HVWHUQEORWVKRZLQJWKHHIIHFWRIIHQUHWLQLGH±0RQWKHH[SUHVVLRQRI6.DSDQGS5HVXOWVDUHUHSUHVHQWDWLYHRIDWOHDVW
WKUHHLQGHSHQGHQWH[SHULPHQWV$FWLQZDVXVHGDSURWHLQORDGLQJFRQWURO$OVRVKRZQDUHEDUJUDSKVRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI
IHQUHWLQLGHRQ6.DSDQGSH[SUHVVLRQ5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. ***p < 0.001 versus control; 
(B) The effect of fenretinide on [3+@WK\PLGLQHLQFRUSRUDWLRQ5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments.
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Figure 5: Effect of NAC on the ABC294640- or SKi-induced increase in p21 and p53 expression and the lack of effect 
on SK1a expression. LNCaP-AI cells were pre-treated with or without NAC (10 mM) for 30 min prior to treatment with ABC294640 
0RU6.L0IRUKA) Western blot showing the effect of NAC on the ABC294640- or SKi-induced increase in p53 and p21 
expression; (B) Western blot showing the lack of effect of NAC on the ABC294640- or SKi-induced proteasomal degradation of SK1a; (C) 
Western blot showing the lack of effect of NAC on the ABC294640-induced proteasomal degradation of Des1. In (A-C) actin was used as 
a protein loading control. Western blot results are representative of at least three independent experiments. Also shown are bar graphs of 
WKHTXDQWL¿FDWLRQRIWKHHIIHFWRI1$&P0RQ6.LQKLELWRULQGXFHGLQFKDQJHVLQSS6.DDQG'HVH[SUHVVLRQ5HVXOWVDUH
H[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. *p < 0.05 versus control, ***p < 0.001 versus control.
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Figure 6: Effect of Des1 and SK1 siRNA on p21 and p53 expression in androgen-independent LNCaP-AI cells. 
Androgen-independent LNCaP-AI cells were treated with scrambled siRNA or SK1 siRNA or Des1 siRNA for 48 h. Western blot showing 
the effect of SK1 siRNA or Des1 siRNA on SK1, Des1, p53 and p21 expression. Actin was used a protein loading control. Results are 
UHSUHVHQWDWLYHRIDWOHDVWWKUHHLQGHSHQGHQWH[SHULPHQWV$OVRVKRZQDUHEDUJUDSKVRIWKHTXDQWL¿FDWLRQRIWKHHIIHFWRI6.VL51$RU
'HVVL51$RQ6.D'HVSDQGSH[SUHVVLRQ5HVXOWVDUHH[SUHVVHGDVPHDQVí6'IRUn = 3 experiments. *p < 0.05, **p < 0.01 
versus scrambled siRNA.
Figure 7: Schematic showing the mechanism by which ABC294640 or SKi induce growth arrest in androgen-
independent LNCaP-AI cells.
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of SK1 and Des1 (with regulation of p21) accompanied by 
non-senescence-dependent pathways, regulated by SK1, 
that impact the sphingolipid rheostat pathway (i.e. relative 
effects of ceramide and S1P). 
The concept of targeting Des1 to promote cancer 
cell growth arrest is supported by several studies. For 
instance, Kraveka et al., [26] demonstrated that siRNA 
knockdown of Des1 in SMS-KCNR neuroblastoma cancer 
cells increased dihydroceramide levels and inhibited cell 
JURZWK ZLWK SURPRWHG FHOO F\FOH DUUHVW DW **7KLV
was associated with a protein phosphatase 1-induced 
dephosphorylation of retinoblastoma protein, which 
UHJXODWHV FHOO F\FOH WUDQVLWLRQ ,Q DGGLWLRQ *DJOLRVWUR
et al., [27] have used the dihydroceramide desaturase 
inhibitor XM462 to increase dihydrocermaide levels and 
WRLQGXFHDXWRSKDJ\LQWKHJDVWULFFDUFLQRPD+&*FHOO
line. This was associated with modulation of cyclin D1 
H[SUHVVLRQ DQG GHOD\HG *6 WUDQVLWLRQ 7KHVH HIIHFWV
were recapitulated with dihydroceramide analogues, which 
FDXVHGFHOOF\FOHGHOD\DWWKH*6WUDQVLWLRQDQGSURPRWHG
autophagy, which was linked with the cell cycle arrest. 
Therefore, we propose that in order to reduce 
androgen-independent prostate cancer progression it is 
necessary to modulate both SK1/Des1 thereby affecting 
de novo ceramide and sphingolipid rheostat pathways. 
This concept suggests that targeting multiple stress 
responsive sphingolipid pathways with a single chemical 
entity is likely to be more effective than targeting a single 
pathway in terms of inducing growth arrest of cancer cells.
MATERIALS AND METHODS
Materials
All general biochemicals were from Sigma (Poole, 
UK). ABC294640 was from MedChemExpress (USA). SKi 
and PF543 were from Merck Biosciences (Nottingham, UK). 
RB-005 and F-02 were synthesized as described previously 
>@0*ZDVIURP(Q]R/LIH6FLHQFHV([HWHU8.
SK2 selective inhibitor (R)-FTY720 methylether (ROMe) 
was synthesized as described previously [16]. Antibodies 
were obtained as follows: anti-actin (#A2066), and anti-p53 
(#P8999) from Sigma (Poole, UK); anti-myc (9E10) from 
Santa Cruz Biotechnology (Santa Cruz, CA), and anti-p21 
(#2947) from New England Biolabs (Oxford, UK); anti-
DES1 (EPR9680), antibody from Abcam; Anti-SK1 (lab 
reference number 48:2) antibody was custom made by 
Abcam using antigens detailed in [28]. DharmaFECTTM 
UHDJHQW217$5*(7SOXV60$57SRRO® SK1, SK2 and 
DES1 siRNAs were from Dharmacon (Cromlington, UK). 
Scrambled siRNA (ALLSTARS Negative control) was from 
Qiagen (Crawley, UK). 
Cell culture
LNCaP-AI (androgen-independent) cells and Jurkat T 
cells were maintained in RPMI supplemented with 1% (v/v) 
L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin 
and 10% (v/v)lipid-stripped fetal calf serum or 10% (v/v) 
fetal bovine serum, respectively, at 37°C with 5% CO
2
.
[3H] thymidine incorporation
/1&D3$,FHOOVDSSUR[FRQÀXHQWLQZHOO
plates were incubated with inhibitors or vehicle (DMSO, 
YY¿QDODVGHWDLOHGLQWKHOHJHQGVIRUK prior 
to the addition of [3H] thymidine (9.25 kBq per well) for 
a further 5 h. Incubations were terminated by removing 
the medium and immediately adding 1 ml of ice cold 10% 
(w/v) trichloroacetic acid and placed on ice for 10 minutes. 
This was replaced with a further 1 ml ice cold 10% (w/v) 
trichloroacetic acid for 10 minutes and repeated once 
more.  Residual nuclear material was dissolved in 0.25 ml 
of 0.1% SDS/0.3 M NaOH. [3H] thymidine uptake was 
TXDQWL¿HG E\ OLTXLGVFLQWLOODWLRQ FRXQWLQJ Radiometric 
YDOXHV PHDQ í 6' ZHUH REWDLQHG IURP  RU PRUH
independent experiments.
Western blotting
Upon treatment, LNCaP-AI cells were lysed 
in sample buffer (62.5 mM Tris-HCl (pH 6.7), 0.5 M 
sodium pyrophosphate, 1.25 mM EDTA, 1.25% (w/v) 
sodium dodecyl sulphate, 0.06% (w/v) bromophenol 
blue, 12.5% (v/v) glycerol (all from Sigma) and 50 mM 
dithiothreitol (Enzo)). Proteins were separated on a 10% 
(v/v) acrylamide/bisacrylamide gel, and transferred 
WR QLWURFHOOXORVH +\ERQG PHPEUDQH *( +HDOWKFDUH
Membranes were blocked in 5% (w/v) BSA (Fisher) in 
TBST buffer (20 mM Tris-HCl (pH 7.5), 48 mM NaCl, 
0.1% (v/v) Tween 20) for 1 hour at room temperature prior 
to incubation with primary antibody (diluted in blocking 
buffer) overnight at 4ºC. Following three washes in TBST, 
membranes were incubated with horse radish peroxidase-
FRQMXJDWHG DQWLPRXVH RU DQWLUDEELW ,J* VHFRQGDU\
antibody (Sigma; diluted in blocking buffer) for 1 hour 
at room temperature. Immunoreactive protein bands were 
visualized using enhanced chemiluminescence, acquired 
DV7,))¿OHVDQGTXDQWL¿HGXVLQJ,PDJH-'HQVLWRPHWULF
YDOXHV UHSUHVHQWHGDVPHDQí6'ZHUHQRUPDOL]HG
using the corresponding data for actin for the same 
samples and were obtained from 3 or more independent 
experiments. Statistical analysis was undertaken using 
one way ANOVA with Tukeys post hoc test.
siRNA transfections
LNCaP-AI cells were transiently transfected with 
VL51$ FRQVWUXFWV DV GHVFULEHG LQ WKH ¿JXUH OHJHQGV
RU VFUDPEOHG VL51$ DV D QHJDWLYH FRQWURO DW D ¿QDO
concentration of 200 nM or 400 nM. Cells were grown 
WR DSSUR[LPDWHO\  FRQÀXHQFH DQG IRU HDFK ZHOO
D PL[WXUH RI  0 VL51$ LQ  O of DNAse/RNAse 
free water and 1.6 O of DharmaFECT® 2 transfection 
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reagent in 150 O of serum free, antibiotic free media 
was prepared. These preparations were incubated for 
5 minutes at room temperature to mix and then combined 
and incubated for 20 minutes at room temperature to allow 
formation of siRNA and DharmaFECT® 2 transfection 
reagent complexes. Next, 800 ȝO of antibiotic-free RPMI 
1640 medium supplemented with 10% (v/v) lipid-stripped 
fetal calf serum and 1% (v/v) L-glutamine were added to 
the transfection mix, which was then gently mixed. This 
was then used to replace cell culture medium and cells 
were incubated at 37°C in 5% CO
2
 for 48 hours.
Des1 assays
Measurement of Des1 activity was performed by 
HPLC using intact Jurkat cells labeled with DhCer-C6-
1%'DVGHVFULEHGSUHYLRXVO\>@%ULHÀ\6 cells/ml 
Jurkat cells were incubated on ice for 30 minutes with 
10 PM DhCer-C6-NBD (Cayman) in 0.5% serum in 
RPMI media. The cells were changed into fresh media 
and treated with inhibitors for 3 hours. The cells were 
harvested and pelleted via centrifugation at 500 g and 
resuspended in 100 ml of H
2
0. The samples were sonicated 
for 30 seconds followed by the addition of 900 ml 
methanol. Immediately before analysis, the samples were 
centrifuged for 3 mins at 13,000 g and transferred to 
+3/&YLDOV([WUDFWHGVDPSOHVOZHUHDQDO\VHGRQ
D:DWHUV+3/&FRXSOHGWRDÀXRUHVFHQFHGHWHFWRUXVLQJ
a 30 cm C18 reverse-phase column eluted with 1 ml/min 
20% H
2
2DQGDFHWRQLWULOHZLWKWULÀXRURDFHWLF
acid. NBD-labelled substrate and product were quantitated 
with excitation and emission wavelengths of 465 nm and 
530 nm, respectively.
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